UCB's Global Corporate Website
Welcome to UCB in the United States

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Sep

22

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Jun

01

Life with MG & What I Wish For Everyone Who is Diagnosed

May

27

My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Feb

25

Recognizing Rare Disease Day Every Day – The Importance of Addressing Unmet Patient Needs

At UCB, we work 365-days-a-year to find new ways to deliver solutions, peace of mind, and opportunities to people living with severe diseases because everyone deserves to live the best life they can.

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Oct

27

Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy

Jun

03

Elevating the Voice of People with MG

This month in honor of Myasthenia Gravis (MG) Awareness Month, we have an opportunity to elevate the voices and needs of people with MG who remind us each day that our collective efforts can directly impact the everyday lives of MG patients – especially during times when immunocompromised individuals can face even more challenges than usual.